Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 493
- Registration Number
- NCT03810313
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT03809611
- Locations
- 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT03804879
- Locations
- 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 450
- Registration Number
- NCT03802630
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Conditions
- Colorectal CancerGastroesophageal CancerRenal Cell Carcinoma
- Interventions
- Drug: Modified FOLFOX6Drug: FOLFIRI
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 167
- Registration Number
- NCT03798626
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT03785405
- Locations
- 🇹🇷
Novartis Investigative Site, Konak-Izmir, Turkey
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
- Conditions
- Liver Transplant Rejection
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT03781414
- Locations
- 🇺🇸
Wash U School of Medicine, Saint Louis, Missouri, United States
🇺🇸Duke Univ Medical Center, Durham, North Carolina, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT03774082
- Locations
- 🇹🇷
Novartis Investigative Site, Antalya, Turkey
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
- Conditions
- Juvenile Psoriatic ArthritisEnthesitis Related Arthritis
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT03769168
- Locations
- 🇺🇸
St Lukes Intermountain Research Center, Boise, Idaho, United States
🇺🇸Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
🇺🇸Legacy Emanuel Research Hospital Portland, Portland, Oregon, United States
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03765788
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany